Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03489967
Other study ID # HYPO-T
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 18, 2018
Est. completion date August 31, 2020

Study information

Verified date September 2020
Source Institut de Recherches Cliniques de Montreal
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

According to guidelines, when a mild-to-moderate hypoglycemia occurs (capillary blood glucose < 4.0 mmol/L), 15-20g of rapidly absorbed carbohydrates should be ingested. Patients should re-test and re-ingest 15-20g carbohydrates every 15 minutes until they recover from hypoglycemia. These recommendations were principally based on two studies conducted in the 80s before the introduction of intensive insulin therapy secondary to the DCCT trial and with insulin formulations with largely different pharmacokinetic profiles from current insulin analogs. Recent studies suggest that with current insulin analogs and intensive therapeutic approach, 15g of carbohydrates may be insufficient to rapidly correct an important proportion of hypoglycemic episodes. It is thus important to determine if the recommended hypoglycemia treatment remains the recommendation.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date August 31, 2020
Est. primary completion date August 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Males and females = 18 years of old.

2. Clinical diagnosis of type 1 diabetes for at least one year.

3. Treatment with multiple daily insulin injections or insulin pump therapy and using insulin analogs (rapid, ultra-rapid and basal).

4. HbA1c = 10%.

Exclusion Criteria:

1. Clinically significant microvascular complications: nephropathy (estimated glomerular filtration rate below 40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator.

2. Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.

3. Known significant cardiac rhythm abnormality based on investigator judgment.

4. Abnormal blood panel and/or anemia (Hb < 100g/L).

5. Ongoing pregnancy or breastfeeding.

6. Severe hypoglycemic episode within 1 month of screening.

7. Known uncorrected hypokalemia (potassium < 3.5 mmol/L; available within the past 3 months).

Study Design


Intervention

Other:
Induced-hypoglycemia test
Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of < 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.

Locations

Country Name City State
Canada Institut de recherches cliniques de Montréal Montréal

Sponsors (1)

Lead Sponsor Collaborator
Institut de Recherches Cliniques de Montreal

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in glucose levels 15 minutes after hypoglycemic treatment Change in glucose levels 15 minutes after hypoglycemic treatment (16g vs. 32g of carbohydrates) when glucose levels at the time of treatment are below 3.0 mmol/L or between 3.0 and 3.5 mmol/L. 15 minutes after hypoglycemic treatment
Secondary Change in glucose levels 20 minutes after hypoglycemic treatment Change in glucose levels 20 minutes after hypoglycemic treatment (16g vs. 32g of carbohydrates) when glucose levels at the time of treatment are below 3.0 mmol/L or between 3.0 and 3.5 mmol/L. 20 minutes after hypoglycemic treatment
Secondary Change in glucose levels 30 minutes after hypoglycemic treatment Change in glucose levels 30 minutes after hypoglycemic treatment (16g vs. 32g of carbohydrates) when glucose levels at the time of treatment are below 3.0 mmol/L or between 3.0 and 3.5 mmol/L. 30 minutes after hypoglycemic treatment
Secondary Change in glucose levels 45 minutes after hypoglycemic treatment Change in glucose levels 45 minutes after hypoglycemic treatment (16g vs. 32g of carbohydrates) when glucose levels at the time of treatment are below 3.0 mmol/L or between 3.0 and 3.5 mmol/L. 45 minutes after hypoglycemic treatment
Secondary Change in glucose levels 60 minutes after hypoglycemic treatment Change in glucose levels 60 minutes after hypoglycemic treatment (16g vs. 32g of carbohydrates) when glucose levels at the time of treatment are below 3.0 mmol/L or between 3.0 and 3.5 mmol/L. 60 minutes after hypoglycemic treatment
Secondary Number of participants with glucose levels above 8.0 mmol/L 1 hour after hypoglycemia correction 60 minutes after hypoglycemia correction
Secondary Number of participants with glucose levels above 10.0 mmol/L 1 hour after hypoglycemia correction 60 minutes after hypoglycemia correction
Secondary Glucose levels 60 minutes after meal consumption 60 minutes after meal consumption
Secondary Glucose levels 90 minutes after meal consumption 90 minutes after meal consumption
Secondary Number of patients for whom hypoglycemia was corrected 10 minutes after hypoglycemic treatment 10 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia was corrected 15 minutes after hypoglycemic treatment 15 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia was corrected 20 minutes after hypoglycemic treatment 20 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia was corrected 25 minutes after hypoglycemic treatment 25 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia was corrected 30 minutes after hypoglycemic treatment 30 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia was corrected 35 minutes after hypoglycemic treatment 35 minutes after hypoglycemic treatment
Secondary Number of hypoglycemic events corrected 10 minutes after hypoglycemic treatment 10 minutes after hypoglycemic treatment
Secondary Number of hypoglycemic events corrected 15 minutes after hypoglycemic treatment 15 minutes after hypoglycemic treatment
Secondary Number of hypoglycemic events corrected 20 minutes after hypoglycemic treatment 20 minutes after hypoglycemic treatment
Secondary Number of hypoglycemic events corrected 25 minutes after hypoglycemic treatment 25 minutes after hypoglycemic treatment
Secondary Number of hypoglycemic events corrected 30 minutes after hypoglycemic treatment 30 minutes after hypoglycemic treatment
Secondary Number of hypoglycemic events corrected 35 minutes after hypoglycemic treatment 35 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia symptoms disappeared 10 minutes after hypoglycemic treatment 10 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia symptoms disappeared 15 minutes after hypoglycemic treatment 15 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia symptoms disappeared 20 minutes after hypoglycemic treatment 20 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia symptoms disappeared 25 minutes after hypoglycemic treatment 25 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia symptoms disappeared 30 minutes after hypoglycemic treatment 30 minutes after hypoglycemic treatment
Secondary Number of patients for whom hypoglycemia symptoms disappeared 35 minutes after hypoglycemic treatment 35 minutes after hypoglycemic treatment
Secondary Number of patients requiring a second treatment 40 minutes after the first hypoglycemic treatment 40 minutes after the first hypoglycemic treatment
Secondary Number of patients requiring a second treatment 15 minutes after the first hypoglycemic treatment 15 minutes after the first hypoglycemic treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4